SCHEMBL982085

SCHEMBL982085

Cn1ccc2cc(C3(Cc4ccccn4)CCN(Cc4ccccc4)C3)ccc21

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 3/20 0.52
SLC6A4 P31645 3/20 0.52
SLC6A3 Q01959 3/20 0.52
CYP2D6 P10635 2/20 0.52
KCNH2 Q12809 1/20 0.52
KDM4E B2RXH2 2/20 0.41
LMNA P02545 1/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 1/20 0.41
FAAH O00519 1/20 0.39
POLB P06746 1/20 0.38
PTK2 Q05397 1/20 0.36
PTK2B Q14289 1/20 0.36
TGFBR1 P36897 1/20 0.36
MAP3K20 Q9NYL2 1/20 0.36
ALDH1A1 P00352 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
CHRM2 P08172 1/20 0.35
TRPC5 Q9UL62 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL985219 0.89 SLC6A2 (0.64) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL980402 0.80 SLC6A2 (0.63) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL985148 0.78 SLC6A2 (0.73) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL12923048 0.74 CYP2D6 (0.46) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL981974 0.74 CYP2D6 (0.46) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL985221 0.72 CYP2D6 (0.45) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL985968 0.72 SLC6A4 (0.54) SLC6A2SLC6A4SLC6A3CYP2D6KDM4E
SCHEMBL983459 0.72 ACHE (0.40) SLC6A2SLC6A4SLC6A3CYP2D6LMNA
SCHEMBL983147 0.72 CYP2D6 (0.44) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL982934 0.70 CYP2D6 (0.42) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257545-B1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMANN LA ROCHE (CH) 2011-08-31 EP disclosed
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMAN-LA ROCHE, INC. (US) 2011-01-27 US disclosed
EP-2257545-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. Hoffmann-La Roche AG (CH) 2010-12-08 EP disclosed
WO-2009115427-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF SLC6A3, MAOB, TPH2 SLC6A2 6/4885SLC6A4 8/4885SLC6A3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.